Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis NSCLC (Stage IIIA, IIIB, or IV), not amenable to curative surgery or radiotherapy~* At least one prior chemotherapy for palliative therapy~* Response Evaluation Criteria In Solid Tumors (RECIST) criteria for disease status assessment~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2~Exclusion Criteria:~* Concurrent administration of any other tumor therapy~* Pregnant or breast feeding~* Serious concomitant disorders~* Inability or unwillingness to take folic acid or vitamin B12 supplementation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed (Type: EXPERIMENTAL): None
- Docetaxel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).